Halozyme Therapeutics
Halozyme Therapeutics, Inc. is an American biopharmaceutical technology company that develops and licenses drug delivery enzymes and subcutaneous drug administration platforms to the global biopharmaceutical industry. The company operates through a single biopharmaceutical licensing segment, commercializing its proprietary ENHANZE drug delivery technology centered on the recombinant human hyaluronidase enzyme (rHuPH20). Its principal revenue drivers stem from recurring royalty streams derived from sales of partners' approved biotherapeutics incorporating ENHANZE, upfront licensing and clinical milestone payments, and bulk enzyme material sales. Halozyme holds a leading global position in subcutaneous biopharmaceutical delivery, maintaining licensing partnerships with major pharmaceutical leaders including Roche, Janssen, Takeda, and Pfizer to enable rapid subcutaneous injection of IV drugs. The enterprise serves international biopharmaceutical developers and biotechnology companies. The company focuses on expanding new drug licensing partnerships for ENHANZE, securing regulatory approvals for partner pipeline candidates, commercializing auto-injector device platforms, and maintaining robust patent protections. Halozyme Therapeutics, Inc. is headquartered in San Diego, California, United States, and its common stock is publicly listed and traded on the Nasdaq Global Select Market.
16 of the funds FundTelligence covers report a position in Halozyme Therapeutics.
- Legal name
- Halozyme Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 16
Funds holding Halozyme Therapeutics
- Handelsbanken Amerika SMB Tema — Handelsbanken · 2.05 % (full portfolio disclosed, October 2026)
- Handelsbanken Helse Tema — Handelsbanken · 1.35 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.2 % (full portfolio disclosed, October 2026)
- Swedbank Robur Healthcare — Swedbank · 1.2 % (full portfolio disclosed, October 2026)
- Schroder ISF Global Convertible Bond — Schroders · 0.86 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.76 % (full portfolio disclosed, October 2026)
- Mercer Global Small Cap Equity Fund — Mercer · 0.41 % (full portfolio disclosed, December 2025)
- JPM Global Value Fund — JPM · 0.3 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 16 funds holding it.